GlassScriptPhysician profile
Nisha Sharma
NPI 1932103769
$14,045.18
in general payments reported to CMS, 2019-2025
45 companies · $1,155 in 2025
The $1,155 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $503 · 2021: $272 · 2022: $5,017 · 2023: $5,652 · 2024: $1,097 · 2025: $1,155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,021 · Long Term Medical Supply Or Device Loan: $3,883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,021.01 |
| Long Term Medical Supply Or Device Loan | $3,883.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pentax of America, INC. | $7,468.33 | 2022-2023 | Video Colonoscope, Nds, Endo Stratus Irrigation Pump |
| Abbvie INC. | $1,497.48 | 2021-2025 | Skyrizi, Vraylar, Ubrelvy |
| Pfizer INC. | $735.60 | 2019-2025 | |
| Lilly USA, LLC | $675.51 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $672.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $454.52 | 2020-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $278.14 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $269.65 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.30 | 2019-2024 | Jardiance |
| Astellas Pharma US INC | $215.92 | 2019-2024 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $134.98 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2020-2025 | Airsupra |
| Abbott Laboratories | $99.27 | 2019-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $91.73 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Dexcom, INC. | $88.32 | 2022-2024 | Dexcom G6 Transmitter |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nisha Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.